Literature DB >> 1465284

The interaction of 5-fluorouracil, hydroxyurea, and radiation in two human head and neck cancer cell lines.

E E Vokes1, M Beckett, T Karrison, R R Weichselbaum.   

Abstract

We have investigated the effects of 5-fluorouracil (5-FU) and hydroxyurea (HU) with radiation on two human head and neck squamous carcinoma cell lines. SQ-20B has a D0 of 239 cGy and an S phase fraction of 37%, while SQ-38 has a D0 of 146 cGy and an S phase fraction of 31%. For SQ-20B the surviving fraction at 100 cGy was significantly reduced (p < 0.05) when cells were exposed to HU or to 5-FU or both chemotherapy agents together with radiation. No significant effect was seen for SQ-38 with either chemotherapy agent alone or in combination with radiation as compared with radiation alone. Therefore, additive cytotoxicity between 5-FU and HU and radiotherapy was observed only in a head and neck cancer cell line with a higher D0 and a higher S phase fraction.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1465284     DOI: 10.1159/000227092

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  4 in total

Review 1.  Oral chemotherapy in head and neck cancer.

Authors:  B E Brockstein; E E Vokes
Journal:  Drugs       Date:  1999       Impact factor: 9.546

2.  Intensive multimodality therapy for carcinoma of the esophagus and gastroesophageal junction.

Authors:  M K Ferguson; L B Reeder; P C Hoffman; D J Haraf; L C Drinkard; E E Vokes
Journal:  Ann Surg Oncol       Date:  1995-03       Impact factor: 5.344

3.  A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation.

Authors:  T Y Seiwert; T Darga; D Haraf; E A Blair; K Stenson; E E W Cohen; J K Salama; V Villaflor; M E Witt; M W Lingen; R R Weichselbaum; E E Vokes
Journal:  Ann Oncol       Date:  2012-10-26       Impact factor: 32.976

4.  A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.

Authors:  E E Vokes; D J Haraf; L C Drinkard; P C Hoffman; M K Ferguson; N J Vogelzang; S Watson; N J Lane; H M Golomb
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.